Identification of a novel polymorphism associated with reduced clozapine concentration in schizophrenia patients—a genome-wide association study adjusting for smoking habits

Abstract excerpt

Abstract Clozapine (CLZ) is the superior antipsychotic drug for treatment of schizophrenia, but exhibits an extensive interpatient pharmacokinetic variability. Here, we conducted a genome-wide association study (GWAS) of CLZ serum concentration adjusting for known smoking habits, which is a major nongenetic factor reducing CLZ levels. The study included 484 patients with 10,283 steady-state serum concentrations...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Asthma and respiratory diseases
• Share to Genetic Associations and Epidemiology
• Share to Schizophrenia research and treatment